Skip to main content

A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials

Publication ,  Conference
D'Amico, AV; Halabi, S; Vogelzang, NJ; Small, EJ
Published in: JOURNAL OF CLINICAL ONCOLOGY
July 15, 2004

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

July 15, 2004

Volume

22

Issue

14

Start / End Page

383S / 383S

Location

New Orleans, LA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

40th Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
D’Amico, A. V., Halabi, S., Vogelzang, N. J., & Small, E. J. (2004). A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 22, pp. 383S-383S). New Orleans, LA: AMER SOC CLINICAL ONCOLOGY.
D’Amico, A. V., S. Halabi, N. J. Vogelzang, and E. J. Small. “A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials.” In JOURNAL OF CLINICAL ONCOLOGY, 22:383S-383S. AMER SOC CLINICAL ONCOLOGY, 2004.

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

July 15, 2004

Volume

22

Issue

14

Start / End Page

383S / 383S

Location

New Orleans, LA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

40th Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences